See more : Big Tech 50 R&D-Limited Partnership (BIGT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of AVEO Pharmaceuticals, Inc. (AVEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVEO Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Amoéba S.A. (ALMIB.PA) Income Statement Analysis – Financial Results
- Carbon Revolution Public Limited Company Warrant (CREVW) Income Statement Analysis – Financial Results
- Ormet Corporation (ORMTQ) Income Statement Analysis – Financial Results
- ML System S.A. (MLS.WA) Income Statement Analysis – Financial Results
- iRhythm Technologies, Inc. (IRTC) Income Statement Analysis – Financial Results
AVEO Pharmaceuticals, Inc. (AVEO)
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.87M | 6.02M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Cost of Revenue | 4.74M | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 34.14M | 4.77M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Gross Profit Ratio | 87.81% | 79.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 26.30M | 22.68M | 17.96M | 20.65M | 25.18M | 23.70M | 12.88M | 38.25M | 68.47M | 91.36M | 101.74M | 86.35M | 51.79M | 41.82M | 29.25M |
| General & Administrative | 0.00 | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 60.81M | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.36M | 11.73M | 8.02M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.11M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Cost & Expenses | 91.85M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 32.00K | 125.00K | 497.00K | 527.00K | 126.00K | 144.26K | 1.17M | 2.17M |
| Interest Expense | -4.05M | 1.61M | 1.82M | 2.19M | 2.37M | 1.95M | 2.31M | 2.39M | 3.13M | 3.50M | 3.84M | 3.39M | 2.81M | 2.09M | 2.44M |
| Depreciation & Amortization | -7.83M | 21.00K | 11.58M | 22.22M | -33.74M | 30.00K | 9.57M | 6.22M | 3.78M | 2.51M | 1.65M | 1.35M | 1.29M | 1.32M | 1.33M |
| EBITDA | -57.39M | -33.96M | 11.20M | -3.14M | -62.55M | -24.81M | -3.13M | -44.13M | -100.13M | -108.38M | 36.14M | -54.05M | -40.09M | -29.07M | -21.21M |
| EBITDA Ratio | -147.62% | -564.18% | 38.91% | -58.01% | -825.32% | -986.36% | -16.44% | -243.51% | -7,743.77% | -561.98% | 21.92% | -120.97% | -193.52% | -147.84% | -192.22% |
| Operating Income | -49.55M | -38.88M | -374.00K | -25.36M | -28.81M | -29.39M | -12.43M | -50.45M | -103.90M | -111.64M | 33.95M | -56.43M | -41.19M | -31.33M | -24.72M |
| Operating Income Ratio | -127.47% | -645.90% | -1.30% | -468.79% | -380.14% | -1,168.71% | -65.32% | -278.37% | -8,035.89% | -578.85% | 20.59% | -126.28% | -198.83% | -159.33% | -223.99% |
| Total Other Income/Expenses | -3.79M | 3.29M | 9.76M | 20.03M | -36.11M | 2.61M | -2.58M | -2.29M | -3.13M | -2.76M | -3.30M | -2.36M | -3.00M | -1.15M | -266.03K |
| Income Before Tax | -53.34M | -35.58M | 9.39M | -5.33M | -64.92M | -26.79M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.19M | -32.47M | -24.98M |
| Income Before Tax Ratio | -137.22% | -591.19% | 32.60% | -98.52% | -856.63% | -1,065.05% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -213.30% | -165.17% | -226.40% |
| Income Tax Expense | 7.83M | 4.90M | 0.00 | 0.00 | 101.00K | 101.00K | -268.00K | 98.00K | 2.00K | 744.00K | 537.00K | 1.03M | -100.06K | 937.81K | 2.17M |
| Net Income | -61.18M | -35.58M | 9.39M | -5.33M | -65.03M | -26.89M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.09M | -32.47M | -24.98M |
| Net Income Ratio | -157.37% | -591.19% | 32.60% | -98.52% | -857.96% | -1,069.07% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -212.82% | -165.17% | -226.40% |
| EPS | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.72 | -22.98 | -22.31 | -202.07 | -155.46 |
| EPS Diluted | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.39 | -22.98 | -22.31 | -202.07 | -155.46 |
| Weighted Avg Shares Out | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 3.97M | 2.56M | 1.98M | 160.70K | 160.70K |
| Weighted Avg Shares Out (Dil) | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 4.15M | 2.56M | 1.98M | 160.70K | 160.70K |
AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Security Camera Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility
Zacks: Analysts Anticipate AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Will Announce Quarterly Sales of $1.48 Million
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Expected to Announce Earnings of -$0.51 Per Share
$1.48 Million in Sales Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Update
Two Sigma Investments LP Sells 89,040 Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals (NASDAQ:AVEO) Shares Up 7.3% Following Insider Buying Activity
Source: https://incomestatements.info
Category: Stock Reports